MERCK & CO INC shareholders Q2 2022

MERCK & CO INC's ticker is MRK and the CUSIP is 58933Y105. A total of 2,965 filers reported holding MERCK & CO INC in Q2 2022. The put-call ratio across all filers is 0.74 and the average weighting 0.7%.

MERCK & CO INC shareholders Q2 2022
NameSharesValueWeighting ↓
MILLER HOWARD INVESTMENTS INC /NY 983,049$89,625,0003.46%
Miramar Capital, LLC 133,362$12,159,0003.44%
SKBA CAPITAL MANAGEMENT LLC 187,525$17,097,0003.42%
EXANE DERIVATIVES 64,879$5,914,298,0003.40%
Founders Capital Management 47,261$4,309,0003.40%
PFM Health Sciences, LP 971,998$88,617,0003.38%
Columbia Asset Management 146,254$13,334,0003.38%
Cutler Capital Management, LLC 95,916$8,745,0003.37%
BRANDES INVESTMENT PARTNERS, LP 1,504,323$137,150,0003.35%
HAMEL ASSOCIATES, INC. 92,585$8,442,0003.33%
Hi-Line Capital Management, LLC 94,729$8,704,0003.31%
FOUNDATION RESOURCE MANAGEMENT INC 203,276$18,533,0003.30%
KLCM Advisors, Inc. 161,943$14,764,0003.28%
Hillman Capital Management, Inc. 98,114$8,945,0003.25%
Red Spruce Capital, LLC 53,397$4,868,0003.24%
Brown Advisory Securities, LLC 37,489$3,420,0003.23%
FWL INVESTMENT MANAGEMENT, LLC 48,742$4,444,0003.23%
MORGAN DEMPSEY CAPITAL MANAGEMENT LLC 115,500$10,530,0003.20%
Demars Financial Group, LLC 61,505$5,607,0003.19%
Howard Capital Management Group, LLC 298,272$27,193,0003.19%
About MERCK & CO INC

Merck & Co Inc. is a leading pharmaceutical company that has been in operation for over a century. The company is known for its innovative research and development of drugs that have helped to improve the health and well-being of millions of people around the world.

Merck & Co Inc. has a strong pipeline of drugs that are in various stages of development. The company's focus on research and development has helped it to stay ahead of its competitors in the pharmaceutical industry. Merck & Co Inc. has a number of drugs that are currently in clinical trials, and the company is optimistic about the potential of these drugs to treat a range of diseases.

One of the key strengths of Merck & Co Inc. is its commitment to sustainability. The company has set ambitious goals to reduce its environmental impact and to promote social responsibility. Merck & Co Inc. has been recognized for its efforts in sustainability, and the company is committed to continuing to make progress in this area.

Merck & Co Inc. has a strong financial position, with a solid balance sheet and a history of consistent earnings growth. The company's strong financial position has allowed it to invest in research and development, and to pursue strategic acquisitions that have helped to expand its product portfolio.

Overall, Merck & Co Inc. is a well-respected pharmaceutical company that has a strong track record of innovation and success. With a focus on sustainability and a commitment to research and development, the company is well-positioned for continued growth and success in the years ahead.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists MERCK & CO INC's shareholders in Q2 2022. To view MERCK & CO INC's shareholder history, click here.